Dermata (NASDAQ: DRMA) CFO adds stock plus new warrants
Rhea-AI Filing Summary
Dermata Therapeutics, Inc. (DRMA) reported that its SVP and CFO, Kyri K. Van Hoose, acquired securities in a private placement. She acquired 102,040 shares of common stock and now directly holds 232,463 common shares. In the same transaction, she received a Series E Warrant and a Series F Warrant, each for 102,040 underlying common shares at an exercise price of $1.47 per share. The common stock and accompanying warrants were purchased together at $1.47 per unit. The warrants become exercisable on the effective date of required stockholder approval, are capped at 9.99% beneficial ownership, and expire five years (Series E) and two years (Series F) after that approval.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Buyer: 102,040 shares
Net Buy
3 txns
Insider
Van Hoose Kyri K.
Role
SVP, CFO
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Series E Warrant (Right to Buy) F1, F2, F3 | 102,040 | -- | -- |
| Grant/Award | Series F Warrant (Right to Buy) F1, F2, F4 | 102,040 | -- | -- |
| Grant/Award | Common Stock F1, F2, F3 | 102,040 | -- | -- |
Holdings After Transaction:
Series E Warrant (Right to Buy) — 102,040 shares (Direct);
Series F Warrant (Right to Buy) — 102,040 shares (Direct);
Common Stock — 232,463 shares (Direct)
Footnotes (4)
- F1. The shares of common stock and accompanying warrants reported herein were purchased together by the Reporting Person from the Issuer in a private placement (the "Private Placement"), which transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Each share of common stock was purchased together with (i) a series E warrant to purchase one share of common stock and (ii) a series F warrant to purchase one share of common stock.
- F2. The purchase price per share of common stock and accompanying warrants was $1.47.
- F3. This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock issuable upon exercise of the warrants issued in the Private Placement. This warrant will expire five years from the effective date of stockholder approval and cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions.
- F4. This warrant will become exercisable beginning on the effective date of stockholder approval of the issuance of the shares of common stock issuable upon exercise of the warrants issued in the Private Placement. This warrant will expire two years from the effective date of stockholder approval and cannot be exercised by the Reporting Person if, after giving effect thereto, the Reporting Person, together with his/her affiliates, would beneficially own, as determined in accordance with Section 13(d) of the Exchange Act, more than 9.99% of the number of shares of the common stock outstanding immediately after giving effect to such exercise, subject to certain exceptions.
Key Figures
Common stock acquired: 102,040 shares
Post-transaction common holdings: 232,463 shares
Series E Warrant underlying shares: 102,040 shares
+5 more
8 metrics
Common stock acquired
102,040 shares
Shares of common stock purchased in the private placement on 2026-08-16
Post-transaction common holdings
232,463 shares
Directly held Dermata Therapeutics common stock after the transaction
Series E Warrant underlying shares
102,040 shares
Underlying common stock for the Series E Warrant granted on 2026-08-16
Series F Warrant underlying shares
102,040 shares
Underlying common stock for the Series F Warrant granted on 2026-08-16
Exercise price of warrants
$1.47 per share
Conversion or exercise price for both Series E and Series F Warrants
Purchase price per unit
$1.47
Price per share of common stock and accompanying warrants in the private placement
Beneficial ownership cap
9.99%
Maximum beneficial ownership allowed upon warrant exercise under the terms disclosed
Series E warrant term
5 years
Expires five years from effective date of required stockholder approval
Key Terms
Private Placement, Section 16(b), Rule 16b-3(d)(1), beneficially own, +1 more
5 terms
Private Placement financial
"shares of common stock and accompanying warrants reported herein were purchased together... in a private placement"
A private placement is a sale of securities directly to a selected group of investors, typically institutions or accredited investors, instead of through a public offering. It lets a company raise money faster and with fewer regulatory steps; for existing shareholders it matters because the newly issued shares, often sold at a discount, increase the share count and can dilute their ownership.
Section 16(b) regulatory
"transaction is exempt from Section 16(b) in accordance with Rule 16b-3(d)(1)"
A federal rule that requires company insiders—like officers, directors and large shareholders—to return any profits made from buying and selling the company’s stock within a six-month window. It matters to investors because it discourages short-term trades that could exploit non-public information and helps protect outside shareholders by creating a simple, enforceable way to recover unfair gains, much like a rule stopping someone from flipping a limited-edition item for quick profit after getting early access.
Rule 16b-3(d)(1) regulatory
"exempt from Section 16(b) in accordance with Rule 16b-3(d)(1) promulgated under the"
beneficially own financial
"cannot be exercised... would beneficially own, as determined in accordance with Section 13(d)"
Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.
Section 13(d) regulatory
"beneficially own, as determined in accordance with Section 13(d) of the Exchange Act"
A Section 13(d) filing is a public disclosure required under U.S. securities law when a person or group acquires more than 5% of a company’s registered equity and may influence control. The filer must report who owns the shares, how they were acquired, and any plans or intentions for the company, so the market and other shareholders can see if a large buyer is attempting a takeover or other strategic move. Think of it like a formal announcement that someone has crossed a threshold and is showing their hand.
FAQ
What did DRMA CFO Kyri K. Van Hoose acquire in this Form 4 filing?
Kyri K. Van Hoose acquired 102,040 shares of Dermata Therapeutics common stock plus Series E and Series F Warrants for 102,040 underlying shares each, all in a private placement transaction with the company.
What is the purchase price reported in the DRMA Form 4 private placement?
The reported purchase price was $1.47 per share of common stock and accompanying warrants. Each unit consisted of one common share plus both a Series E warrant and a Series F warrant to buy additional Dermata Therapeutics common stock.
What are the key terms of the Series E and Series F Warrants reported for DRMA?
Both the Series E and Series F Warrants have an exercise price of $1.47 per share, become exercisable upon effective stockholder approval, carry a 9.99% beneficial ownership cap, and expire five years (Series E) and two years (Series F) after that approval date.
Are the DRMA warrants immediately exercisable according to this Form 4?
No. The Form 4 states the warrants become exercisable beginning on the effective date of stockholder approval for the warrant-related share issuance, with a 9.99% beneficial ownership limitation applying to any exercise.
Was this DRMA insider transaction under a Rule 10b5-1 trading plan?
No. The filing’s Rule 10b5-1 checkbox is not marked as an affirmative plan, and the footnotes describe the acquisition as a private placement transaction exempt under Rule 16b-3(d)(1) of the Exchange Act.
AI-generated analysis. How Rhea-AI works. Not financial advice.
